Drug Profile


Alternative Names: Alatrofloxacin injection; Alatrofloxacin IV; CP-116,517; Trovan IV; Turvel IV

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antibacterials; Fluoroquinolones
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Bacterial infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Bacterial-infections in Japan (IV, Infusion)
  • 19 Jun 2002 A clinical study has been added to the adverse events and Bacterial Infections therapeutic trials sections
  • 23 Oct 2000 Pfizer and Roerig have voluntarily withdrawn its marketing authorisations for both alatrofloxacin and trovafloxacin in the European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top